Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 7/20 | 0.42 |
| ▸ | IDH1 | O75874 | 1/20 | 0.41 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.38 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.38 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.38 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.38 |
| ▸ | LGMN | Q99538 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2729800 | 0.88 | IDH1 (0.41) | PIK3CAIDH1GPR119MEN1KMT2A | |
| SCHEMBL2126993 | 0.87 | PIK3CA (0.46) | PIK3CAMEN1KMT2APIK3CDPIK3CB | |
| SCHEMBL2126408 | 0.81 | KDM1A (0.36) | GPR119USP30 | |
| SCHEMBL2124487 | 0.76 | PIK3CA (0.49) | PIK3CAMEN1KMT2APIK3CDPIK3CB | |
| SCHEMBL28521491 | 0.75 | NR1H2 (0.42) | PIK3CAPIK3CDPIK3CBUSP30SMN1; SMN2 | |
| SCHEMBL22471426 | 0.75 | PIK3CA (0.40) | PIK3CAUSP30SMN1; SMN2 | |
| SCHEMBL29966436 | 0.75 | PIK3CA (0.40) | PIK3CAUSP30SMN1; SMN2 | |
| SCHEMBL2126046 | 0.75 | PIK3CA (0.44) | PIK3CAMEN1KMT2APIK3CDPIK3CB | |
| SCHEMBL2123930 | 0.73 | PIK3CA (0.56) | PIK3CAIDH1 | |
| SCHEMBL30898670 | 0.72 | NOTUM (0.53) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-8765940-B2 | Heterocyclic compounds and their uses | AMGEN INC. (US) | 2014-07-01 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2012-04-19 | — | — | US | disclosed |
| WO-2010151737-A2 | HETEROCYCLIC COMPOUNDS AND THEIR USES | AMGEN INC. (US) | 2010-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094972-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USES | MCL1, MALT1, BCL9 | PIK3CA 28/4885IDH1 1581/4885GPR119 2093/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.